

**Wright Medical Group N.V.**  
**Reconciliation of Non-GAAP Combined Organic and Pro Forma Net Sales to Net Sales**  
(dollars in thousands--unaudited)

<b>Three months ended June 30, 2019</b>			
	<b>Legacy Wright (organic)</b>	<b>Standalone Cartiva</b>	<b>Wright Medical Group N.V.</b>
<b>U.S.</b>			
Lower extremities	\$ 60,168	\$ 6,664	\$ 66,832
Upper extremities	80,146	—	80,146
Biologics	23,588	—	23,588
Sports med & other	1,980	—	1,980
<b>Total U.S.</b>	<b>\$ 165,882</b>	<b>\$ 6,664</b>	<b>\$ 172,546</b>
<b>International</b>			
Lower extremities	\$ 15,776	\$ 1,207	\$ 16,983
Upper extremities	31,154	—	31,154
Biologics	6,331	—	6,331
Sports med & other	2,720	—	2,720
<b>Total International</b>	<b>\$ 55,981</b>	<b>\$ 1,207</b>	<b>\$ 57,188</b>
<b>Global</b>			
Lower extremities	\$ 75,944	\$ 7,871	\$ 83,815
Upper extremities	111,300	—	111,300
Biologics	29,919	—	29,919
Sports med & other	4,700	—	4,700
<b>Total net sales</b>	<b>\$ 221,863</b>	<b>\$ 7,871</b>	<b>\$ 229,734</b>

<b>Three months ended July 1, 2018</b>			
	<b>Standalone Wright Medical Group N.V.</b>	<b>Standalone Cartiva</b>	<b>Non-GAAP combined pro forma</b>
<b>U.S.</b>			
Lower extremities	\$ 59,464	\$ 7,676	\$ 67,140
Upper extremities	70,171	—	70,171
Biologics	20,234	—	20,234
Sports med & other	1,706	—	1,706
<b>Total U.S.</b>	<b>\$ 151,575</b>	<b>\$ 7,676</b>	<b>\$ 159,251</b>
<b>International</b>			
Lower extremities	\$ 15,680	\$ 327	\$ 16,007
Upper extremities	29,137	—	29,137
Biologics	6,582	—	6,582
Sports med & other	2,426	—	2,426
<b>Total International</b>	<b>\$ 53,825</b>	<b>\$ 327</b>	<b>\$ 54,152</b>
<b>Global</b>			
Lower extremities	\$ 75,144	\$ 8,003	\$ 83,147
Upper extremities	99,308	—	99,308
Biologics	26,816	—	26,816
Sports med & other	4,132	—	4,132
<b>Total net sales</b>	<b>\$ 205,400</b>	<b>\$ 8,003</b>	<b>\$ 213,403</b>

**Three months ended June 30, 2019**

**Non-GAAP organic and combined pro forma constant currency  
net sales growth/(decline)**

	<b>Legacy Wright (organic) constant currency</b>	<b>Standalone Cartiva</b>	<b>Non-GAAP combined pro forma constant currency</b>
<b>U.S.</b>			
Lower extremities	1.2%	N/A	(0.5)%
Upper extremities	14.2%	N/A	14.2%
Biologics	16.6%	N/A	16.6%
Sports med & other	16.1%	N/A	16.1%
<b>Total U.S.</b>	9.4%	N/A	8.3%
<b>International</b>			
Lower extremities	5.2%	N/A	10.6%
Upper extremities	12.6%	N/A	12.6%
Biologics	(0.6)%	N/A	(0.6)%
Sports med & other	18.6%	N/A	18.6%
<b>Total International</b>	9.1%	N/A	10.7%
<b>Global</b>			
Lower extremities	2.0%	N/A	1.7%
Upper extremities	13.8%	N/A	13.8%
Biologics	12.4%	N/A	12.4%
Sports med & other	17.6%	N/A	17.6%
<b>Total net sales</b>	9.4%	N/A	8.9%

**Six months ended June 30, 2019**

	<b>Legacy Wright (organic)</b>	<b>Standalone Cartiva</b>	<b>Wright Medical Group N.V.</b>
<b>U.S.</b>			
Lower extremities	\$ 123,031	\$ 15,109	\$ 138,140
Upper extremities	161,873	—	161,873
Biologics	46,228	—	46,228
Sports med & other	4,072	—	4,072
<b>Total U.S.</b>	<u>\$ 335,204</u>	<u>\$ 15,109</u>	<u>\$ 350,313</u>
<b>International</b>			
Lower extremities	\$ 30,536	\$ 1,998	\$ 32,534
Upper extremities	60,619	—	60,619
Biologics	10,869	—	10,869
Sports med & other	5,526	—	5,526
<b>Total International</b>	<u>\$ 107,550</u>	<u>\$ 1,998</u>	<u>\$ 109,548</u>
<b>Global</b>			
Lower extremities	\$ 153,567	\$ 17,107	\$ 170,674
Upper extremities	222,492	—	222,492
Biologics	57,097	—	57,097
Sports med & other	9,598	—	9,598
<b>Total net sales</b>	<u>\$ 442,754</u>	<u>\$ 17,107</u>	<u>\$ 459,861</u>

**Six months ended July 1, 2018**

	<b>Standalone Wright Medical Group N.V.</b>	<b>Standalone Cartiva</b>	<b>Non-GAAP combined pro forma</b>
<b>U.S.</b>			
Lower extremities	\$ 116,287	\$ 16,287	\$ 132,574
Upper extremities	137,829	—	137,829
Biologics	38,399	—	38,399
Sports med & other	3,853	—	3,853
<b>Total U.S.</b>	<b>\$ 296,368</b>	<b>\$ 16,287</b>	<b>\$ 312,655</b>
<b>International</b>			
Lower extremities	\$ 31,007	\$ 623	\$ 31,630
Upper extremities	58,731	—	58,731
Biologics	11,839	—	11,839
Sports med & other	5,992	—	5,992
<b>Total International</b>	<b>\$ 107,569</b>	<b>\$ 623</b>	<b>\$ 108,192</b>
<b>Global</b>			
Lower extremities	\$ 147,294	\$ 16,910	\$ 164,204
Upper extremities	196,560	—	196,560
Biologics	50,238	—	50,238
Sports med & other	9,845	—	9,845
<b>Total net sales</b>	<b>\$ 403,937</b>	<b>\$ 16,910</b>	<b>\$ 420,847</b>

**Six months ended June 30, 2019**

**Non-GAAP organic and combined pro forma constant currency  
net sales growth/(decline)**

	<b>Legacy Wright (organic) constant currency</b>	<b>Standalone Cartiva</b>	<b>Non-GAAP combined pro forma constant currency</b>
<b>U.S.</b>			
Lower extremities	5.8%	N/A	4.2%
Upper extremities	17.4%	N/A	17.4%
Biologics	20.4%	N/A	20.4%
Sports med & other	5.7%	N/A	5.7%
<b>Total U.S.</b>	<b>13.1%</b>	<b>N/A</b>	<b>12.0%</b>
<b>International</b>			
Lower extremities	4.0%	N/A	8.3%
Upper extremities	9.9%	N/A	9.9%
Biologics	(4.3)%	N/A	(4.3)%
Sports med & other	(1.6)%	N/A	(1.6)%
<b>Total International</b>	<b>6.0%</b>	<b>N/A</b>	<b>7.2%</b>
<b>Global</b>			
Lower extremities	5.4%	N/A	5.0%
Upper extremities	15.2%	N/A	15.2%
Biologics	14.6%	N/A	14.6%
Sports med & other	1.3%	N/A	1.3%
<b>Total net sales</b>	<b>11.2%</b>	<b>N/A</b>	<b>10.8%</b>

**Wright Medical Group N.V.**  
**Supplemental Net Sales Information**  
(unaudited)

**Three months ended June 30, 2019 net sales growth/(decline)**

<b>Product line</b>	<b><u>U.S. as reported</u></b>	<b><u>Int'l constant currency</u></b>	<b><u>Int'l as reported</u></b>	<b><u>Global constant currency</u></b>	<b><u>Global as reported</u></b>
Lower extremities	12%	13%	8%	12%	12%
Upper extremities	14%	13%	7%	14%	12%
Biologics	17%	(1)%	(4%)	12%	12%
Sports med & other	16%	19%	12%	18%	14%
<b>Total net sales</b>	14%	11%	6%	13%	12%

**Six months ended June 30, 2019 net sales growth/(decline)**

<b>Product line</b>	<b><u>U.S. as reported</u></b>	<b><u>Int'l constant currency</u></b>	<b><u>Int'l as reported</u></b>	<b><u>Global constant currency</u></b>	<b><u>Global as reported</u></b>
Lower extremities	19%	10%	5%	17%	16%
Upper extremities	17%	10%	3%	15%	13%
Biologics	20%	(4)%	(8%)	15%	14%
Sports med & other	6%	(2)%	(8%)	1%	(3%)
<b>Total net sales</b>	18%	8%	2%	15%	14%

**Wright Medical Group N.V.**  
**Reconciliation of Adjusted Non-GAAP Earnings Per Share to Net Loss from Continuing Operations Per Share**  
(dollars in thousands, except per share data--unaudited)

	Three months ended		Six months ended	
	June 30, 2019	July 1, 2018	June 30, 2019	July 1, 2018
<b>Net loss from continuing operations, as reported</b>	\$ (18,932)	\$ (90,621)	\$ (49,188)	\$ (110,528)
Weighted-average diluted shares outstanding	126,267	106,095	126,040	106,000
<b>Net loss from continuing operations per share, as reported</b>	<u>\$ (0.15)</u>	<u>\$ (0.85)</u>	<u>\$ (0.39)</u>	<u>\$ (1.04)</u>
Reconciling items:				
Non-cash interest expense on convertible notes <sup>1</sup>	12,133	12,275	24,398	24,287
Net loss on exchange or extinguishment of debt <sup>2</sup>	—	39,935	14,274	39,935
Derivatives mark-to-market adjustments <sup>2</sup>	(816)	32,879	(1,812)	34,573
Inventory step-up amortization	352	—	704	—
Transition costs	597	1,325	1,021	2,235
Foreign currency translation expense <sup>2</sup>	24	1,893	(276)	2,656
CVR mark-to-market adjustments <sup>2</sup>	—	(2,523)	(420)	(6,447)
Contingent consideration fair value adjustment <sup>2</sup>	1,652	365	2,028	779
Tax expense due to change in tax rates on income from deferred intercompany transactions <sup>3</sup>	2,566	—	5,132	—
Gain on investments, net <sup>2</sup>	(3,266)	—	(3,266)	—
U.S. tax benefit resulting from income from discontinued operations <sup>3</sup>	—	(6,183)	—	(6,183)
Tax effect of reconciling items <sup>4</sup>	(5)	1,069	(10)	859
<b>Non-GAAP net loss from continuing operations, as adjusted</b>	<u>\$ (5,695)</u>	<u>\$ (9,586)</u>	<u>\$ (7,415)</u>	<u>\$ (17,834)</u>
Add back amortization of intangible assets	7,862	6,009	15,449	13,150
<b>Adjusted non-GAAP earnings</b>	<u>\$ 2,167</u>	<u>\$ (3,577)</u>	<u>\$ 8,034</u>	<u>\$ (4,684)</u>
Adjusted non-GAAP weighted-average diluted shares outstanding <sup>5</sup>	128,616	106,095	128,401	106,000
<b>Adjusted non-GAAP earnings per share</b>	<u>\$ 0.02</u>	<u>\$ (0.03)</u>	<u>\$ 0.06</u>	<u>\$ (0.04)</u>

<sup>1</sup> Impacting interest expense, net.

<sup>2</sup> Impacting other (income) expense, net.

<sup>3</sup> Impacting provision from income taxes.

<sup>4</sup> Determined based upon the effective tax rate in the jurisdiction in which the expense was incurred.

<sup>5</sup> Adjusted non-GAAP weighted-average diluted shares outstanding includes common stock equivalents of 2.3 million and 2.4 million for the three and six months ended June 30, 2019, respectively, based on the income position of our adjusted non-GAAP earnings.

**Wright Medical Group N.V.**  
**Reconciliation of Non-GAAP Adjusted EBITDA to Net Loss from Continuing Operations**  
(dollars in thousands--unaudited)

	Three months ended		Six months ended	
	June 30, 2019	July 1, 2018	June 30, 2019	July 1, 2018
<b>Net loss from continuing operations</b>	\$ (18,932)	\$ (90,621)	\$ (49,188)	\$ (110,528)
Interest expense, net	19,995	20,678	39,690	40,490
Provision (benefit) from income taxes	3,434	(4,462)	7,045	(4,257)
Depreciation	16,172	13,883	31,673	28,382
Amortization	7,862	6,009	15,449	13,150
<b>Non-GAAP EBITDA</b>	<b>\$ 28,531</b>	<b>\$ (54,513)</b>	<b>\$ 44,669</b>	<b>\$ (32,763)</b>
Reconciling items impacting EBITDA:				
Non-cash share-based compensation expense	7,623	6,061	15,244	11,079
Other (income) expense, net	(1,831)	72,747	11,064	71,747
Inventory step-up amortization	352	—	704	—
Transition costs	597	1,325	1,021	2,235
<b>Non-GAAP adjusted EBITDA</b>	<b>\$ 35,272</b>	<b>\$ 25,620</b>	<b>\$ 72,702</b>	<b>\$ 52,298</b>
Net sales from continuing operations	229,734	205,400	459,861	403,937
<b>Non-GAAP adjusted EBITDA margin</b>	<b>15.4%</b>	<b>12.5%</b>	<b>15.8%</b>	<b>12.9%</b>

**Wright Medical Group N.V.**  
**Reconciliation of Non-GAAP Adjusted Gross Margins to Gross Margins from Continuing Operations**  
(dollars in thousands--unaudited)

	Three months ended		Six months ended	
	June 30, 2019	July 1, 2018	June 30, 2019	July 1, 2018
<b>Gross profit from continuing operations, as reported</b>	\$ 181,396	\$ 159,842	\$ 365,206	\$ 317,240
<b>Gross margins from continuing operations, as reported</b>	<b>79.0 %</b>	<b>77.8 %</b>	<b>79.4 %</b>	<b>78.5 %</b>
Reconciling items impacting gross profit:				
Inventory step-up amortization	352	—	704	—
Transition costs	—	1,326	—	2,236
<b>Non-GAAP gross profit from continuing operations, as adjusted</b>	<b>\$ 181,748</b>	<b>\$ 161,168</b>	<b>\$ 365,910</b>	<b>\$ 319,476</b>
Net sales from continuing operations	229,734	205,400	459,861	403,937
<b>Non-GAAP adjusted gross margins from continuing operations</b>	<b>79.1%</b>	<b>78.5%</b>	<b>79.6%</b>	<b>79.1%</b>

**Wright Medical Group N.V.**  
**Reconciliation of Other Non-GAAP Financial Measures to Other As Reported Results**  
(dollars in thousands--unaudited)

	<u>Three months ended</u>		<u>Six months ended</u>	
	<u>June 30, 2019</u>	<u>July 1, 2018</u>	<u>June 30, 2019</u>	<u>July 1, 2018</u>
<b>Net sales</b>	\$ 229,734	\$ 205,400	\$ 459,861	\$ 403,937
<b>Selling, general and administrative expense, as reported</b>	\$ 152,112	\$ 140,826	\$ 305,418	\$ 278,074
Selling, general and administrative expense as a percentage of net sales, as reported	66.2 %	68.6 %	66.4 %	68.8 %
Reconciling items impacting selling, general and administrative expense:				
Transition costs	597	—	1,021	—
<b>Selling, general and administrative expense, as adjusted</b>	<b>\$ 151,515</b>	<b>\$ 140,826</b>	<b>\$ 304,397</b>	<b>\$ 278,074</b>
<b>Selling, general and administrative expense as a percentage of net sales, as adjusted</b>	<b>66.0%</b>	<b>68.6%</b>	<b>66.2%</b>	<b>68.8%</b>